This market report summarizes the results of HTStec’s 4th global web-based benchmarking survey on cell-based label-free (LF) detection carried out in July and August 2014. The study also examined in detail the current market landscape, application areas and interest in purchasing new products/systems.HTS Metrics & Future Direction Trends 2014HTStec

This market report summarizes the results of HTStec’s global web-based benchmarking survey on high throughput screening (HTS) metrics and future directions carried out in July 2014. The survey was initiated by HTStec as part of its tracking of life science marketplaces and to update our previous report (April 2012). It followed an approach from Pharma to benchmark recent HTS metrics.Label-Free Binding Analysis Trends 2014HTStec

This market report summarizes the results of HTStec’s 4th global web-based benchmarking survey on label-free (LF) binding analysis carried out in July 2014. The study was initiated by HTStec as part of its regular (every 2 years) tracking of this life science marketplace. The questionnaire was compiled to address the needs and interests of the LF binding analysis vendor community.Epigenetic Modification Screening Trends 2014HTStec

This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace. Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient population—the field of stratified medicine.MicroRNAs and ExosomesSelect Biosciences Ltd

In this report, we focus upon the microRNA research marketplace from the perspective of the translational opportunities in these spaces. The focus of this field is moving from basic research towards the utility of associations of microRNA expression patterns in disease.Advances in Ion Channel Drug DiscoveryBusiness Insights

The report highlights the most promising areas for ion channel discovery enabled by technology and target validation advances. Channel families with major potential are discussed to highlight the most promising areas for investigation. New technologies and the companies exploiting these are identified. The relative prospects of programs in late-stage development are assessed.

The aim of this study is to understand the mechanism behind the association between single nucleotide polymorphisms (SNPs), lying in non-coding regions near or within RAD51B and RAD23B, and prostate cancer risk by analysing their interactions with the whole genome using Circular Chromosome Conformation Capture (4C).CRISPR-Cas9 genome editing utilizing chemically synthesized RNAGE Healthcare Dharmacon, Inc.

Combined automated qPCR and NGS Sentosa workflow is a reliable and efficient in vitro diagnostics (IVD) tool for the detection and/or quantitation of a wide range of bacterial and viral pathogens as well as gene mutations.A Synthetic CRISPR-Cas9 System for Homology-directed RepairDharmacon (part of GE Healthcare)

CRISPR-Cas9 gene editing using synthetic crRNA:tracrRNA or sgRNA is highly efficient and easy to use. Synthetic crRNA:tracrRNA is uniquely suited to in vitro and in vivo applications, in particular, DNA-free approach with Cas9 mRNA. Chemical synthesis of guide RNAs allows accurate and rapid production of arrayed crRNA libraries for high-confidence, loss-of-function screens.

This study demonstrates the ability of the IntelliQube along with Array Tape®, to successfully achieve two multiplexed SNP genotyping results in a single well and decrease thermal cycling times without compromising data quality. The combination of achieving two results per reaction well and shortened cycling times dramatically increases overall throughput. Cells in Double Emulsions for FACS SortingDolomite